Bristol Myers Squibb announced FDA approval to expand Breyanzi’s (lisocabtagene maraleucel) indication to include third‑line marginal zone lymphoma, making it the first CAR‑T therapy cleared for this rare, indolent non‑Hodgkin lymphoma subtype. The approval follows submission data showing clinical benefit in heavily pretreated patients. BMS positioned the approval as broadening CAR‑T utility beyond more common B‑cell malignancies and underscored the company’s strategy to extend indications through focused registrational work and post‑market evidence generation. Clarification: CAR‑T therapies are autologous cell therapies engineered to target tumor antigens; approvals in new lymphoma subtypes can expand patient access but also raise questions about manufacturing capacity and payer coverage for smaller patient populations.